Skip to content

All Ligaments Left In Knee Arthroplasty Trial

Multi-center Clinical Study of Vanguard XP Bicruciate Knee System

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03302013
Acronym
ALLIKAT
Enrollment
260
Registered
2017-10-04
Start date
2016-09-05
Completion date
2022-01-31
Last updated
2017-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Osteoarthritis of Knee Nos

Keywords

Arthroplasty, Knee, Bicruciate retaining, Vanguard XP, Vanguard CR, Surgery, Zimmer Biomet, Joint Replacement, Osteoarthritis

Brief summary

Compare the clinical and patient reported outcomes of the Vanguard XP Knee System to the Vanguard CR Knee System in patients with antero-medial osteoarthritis of the knee with an intact anterior cruciate ligament.

Detailed description

The purpose of the proposed ALLIKAT study (All Ligaments Left in Knee Arthroplasty Trial) is to evaluate the early outcome of a Total Knee Replacement device that retains both cruciate (Vanguard XP) by comparing it with a control group of patients implanted with an established single cruciate retaining device (Vanguard CR). The study also aims to examine short and long term descriptive cohort outcome data. A small preference cohort group of 60 patients receiving the Vanguard XP Knee System will be recruited alongside the RCT group. This data will be used to confirm the external validity of the RCT group and to contribute to the safety data for the British Orthopaedic Association's Beyond Compliance Programme. Evaluation will include intra-operative and post-operative complications, longer term survivorship and patient reported outcome measures.

Interventions

PROCEDUREVanguard XP Bi-cruciate Retaining Knee Replacement System

Newer design of knee replacement retaining the Anterior Cruciate Ligament as well as the Posterior Cruciate Ligament.

PROCEDUREVanguard CR Single Cruciate Retaining Knee System

Current 'gold standard' for total knee replacement which retains Posterior Cruciate Ligament but sacrifices the Anterior Cruciate Ligament, instead providing artificial support.

Sponsors

Zimmer Biomet
CollaboratorINDUSTRY
University of Copenhagen
CollaboratorOTHER
University of Oxford
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Primary Osteoarthritis of the knee involving one or more compartments of the joint. * Intact Anterior and Posterior Cruciate Ligaments. * Intact collateral ligaments. * Correctable coronal deformity. * No more than 15 degrees of fixed flexion deformity.

Exclusion criteria

* Age under 18 years. * Revision knee replacement surgery. * Rheumatoid Arthritis. * Traumatic aetiology. * History or clinical signs of ACL rupture. * Previous arthroscopy related to ACL injury or reconstruction. * Correction of a flexion contracture that may require extensive resection of distal femur. * Altered pain perception and / or neurologic affection (for example as a complication arising from diabetes). * Unable to consent for themselves. * Patients with language or cognitive issues that may prevent them completing the follow up requirements. * Contraindications for the device: * Cementless application of components. * BMI ≥40 kg/m2. * Use of Anterior Stabilized Bearings. * Patients with severe pre-operative varus or valgus deformity ≥ 15 degrees. * Correction or revision of previous joint replacement procedure on index knee. * Infection. * Sepsis.Osteomyelitis. * Osteoporosis (requiring treatment). * Relative contraindications include: * Unco-operative patient or patient with neurologic disorders who is incapable of following directions. * Osteoporosis. * Metabolic disorders which may impair bone formation. * Osteomalacia. * Distant foci of infections which may spread to the implant site. * Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram. * Vascular insufficiency, muscular atrophy, neuromuscular disease. * Incomplete or deficient soft tissue surrounding the knee, including the anterior cruciate ligament.

Design outcomes

Primary

MeasureTime frameDescription
Oxford Knee Score-Activity & Participation Questionnaire (OKS-APQ)3 years post randomisationPatient Reported Outcome Score - disease specific

Secondary

MeasureTime frameDescription
EQ-5D-3LPost-operation (within 6 weeks); 1 & 3 years post randomisationQuality of Life Patient Reported Outcome Score
Forgotten Joint ScorePost operation (within 6 weeks), 1, 2 & 3 years post randomisationPatient Reported Outcome Score - disease specific
American Knee Society ScorePost operation (within 6 weeks), 1, 2 & 3 years post randomisationFunctional Assessment of the knee
ComplicationsPost operation (within 6 weeks), 1 & 3 years post randomisationAdverse events and complications related to the knee surgery

Other

MeasureTime frameDescription
Radiographic Assessment1 & 3 Years Post RandomisationEvaluation of x-rays to assess Alignment, Radiolucency, Loosening, Fixation/Migration

Countries

United Kingdom

Contacts

Primary ContactRachel Dorman
ALLIKAT@ndorms.ox.ac.uk00441865227715
Backup ContactCushla Cooper
ALLIKAT@ndorms.ox.ac.uk00441865737643

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026